The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects.
Open accessAbstract
Somatostatin is a 14 amino acid peptide that inhibits pancreatic exocrine and endocrine secretion. Its clinical application has been limited by its very short half life, necessitating continuous intravenous infusion. Octreotide is an 8 amino acid synthetic analogue of somatostatin that possesses similar pharmacological effects. It has a much longer duration of action, however, and can be given subcutaneously. Both the intravenous and subcutaneous routes of injection of octreotide are well tolerated. Peak serum concentrations occur within 30 minutes after subcutaneous administration and within four minutes of a three minute intravenous infusion. Serum concentration increases linearly with dose. Octreotide is distributed rapidly, mainly in the plasma, where it is 65% protein bound. The elimination half life is about 1.5 hours and about 32% of a subcutaneous dose is excreted in the urine as unchanged octreotide. Octreotide inhibits gastroenteropancreatic secretion, especially of insulin, glucagon, pancreatic polypeptide, gastric inhibitory polypeptide, and gastrin. It also inhibits both release of thyroid stimulating hormone and growth hormone secretion in response to exercise, insulin induced hypoglycaemia, and argenine stimulation. Octreotide reduces splanchnic blood flow in healthy volunteers and hepatic venous pressure in cirrhotic patients. It can accelerate or delay gastric emptying, prolong transit time at moderate to high doses, stimulate motility at low doses, and inhibit gall bladder emptying. Octreotide considerably inhibits pentagastrin stimulated gastric acid secretion and significantly diminishes exocrine pancreatic function (amylase, trypsin, lipase). Octreotide increases intestinal transit time and decreases endogenous fluid secretion in the jejunum and ileum, thus increasing the absorption of water and electrolytes.(ABSTRACT TRUNCATED AT 250 WORDS)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone
Brazeau, P., Vale, W., Burgus, R., Ling, N., Butcher, M., Rivier, J., & Guillemin, R. (1973) · Science · doi:10.1126/science.179.4068.77 · Cited by 3,532
SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action
Bauer, W., Briner, U., Doepfner, W., Haller, R., Huguenin, R., Marbach, P., Petcher, T. J., & Pless, J. (1982) · Life Sciences · doi:10.1016/0024-3205(82)90087-x · Cited by 1,331
N‐terminally extended somatostatin: The primary structure of somatostatin‐28
Pradayrol, L., Jörnvall, H., Mutt, V., & Ribet, A. (1980) · FEBS Letters · doi:10.1016/0014-5793(80)81310-x · Cited by 526
GROWTH-HORMONE RELEASE-INHIBITING HORMONE IN GASTROINTESTINAL AND PANCREATIC D CELLS
Polak, J., Grimelius, L., Pearse, A. G. E., Bloom, S. R., & Arimura, A. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92198-4 · Cited by 522
Somatostatin Cell Processes as Pathways for Paracrine Secretion
Larsson, L.-I., Goltermann, N., de Magistris, L., Rehfeld, J. F., & Schwartz, T. W. (1979) · Science · doi:10.1126/science.382360 · Cited by 511
A potent cyclic hexapeptide analogue of somatostatin
Veber, D. F., Freidinger, R. M., Perlow, D. S., Paleveda, W. J., Holly, F. W., Strachan, R. G., Nutt, R. F., Arison, B. H., Homnick, C., Randall, W. C., et al. (1981) · Nature · doi:10.1038/292055a0 · Cited by 418
Immunoreactive somatostatin is present in discrete cells of the endocrine pancreas.
Dubois, M. P. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.4.1340 · Cited by 337
INFLUENCE OF SOMATOSTATIN ON CARBOHYDRATE DISPOSAL AND ABSORPTION IN DIABETES MELLITUS
Wahren, J., & Felig, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91142-9 · Cited by 233
Highly active cyclic and bicyclic somatostatin analogues of reduced ring size
VEBER, D. F., HOLLY, F. W., NUTT, R. F., BERGSTRAND, S. J., BRADY, S. F., HISRSCHMANN, R., GLITZER, M. S., & SAPERSTEIN, R. (1979) · Nature · doi:10.1038/280512a0 · Cited by 213
Lembcke, B., Creutzfeldt, W., Schleser, S., Ebert, R., Shaw, C., & Koop, I. (1987) · Digestion · doi:10.1159/000199408 · Cited by 204
Cited by
Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas
Oronsky, B., Ma, P. C., Morgensztern, D., & Carter, C. A. (2017) · Neoplasia · doi:10.1016/j.neo.2017.09.002 · Cited by 763
Strategic Approaches to Optimizing Peptide ADME Properties
Di, L. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9687-3 · Cited by 669
Strategies to improve plasma half life time of peptide and protein drugs
Werle, M., & Bernkop-Schnürch, A. (2006) · Amino Acids · doi:10.1007/s00726-005-0289-3 · Cited by 660
Peptides as a platform for targeted therapeutics for cancer: peptide–drug conjugates (PDCs)
Cooper, B. M., Iegre, J., O' Donovan, D. H., Ölwegård Halvarsson, M., & Spring, D. R. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00556h · Cited by 414
MODLIN, I. M., PAVEL, M., KIDD, M., & GUSTAFSSON, B. I. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04174.x · Cited by 410
Metadata
- Authors
- Harris, A. G.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 1994
- Volume
- 35
- Issue
- 3 Suppl
- Pages
- S1-S4
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W1981547344
- Cited by
- 266
- References
- 19
- FWCI
- 3.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. https://app.cochat.ai/papers/10.1136/gut.35.3_suppl.s1
- The paper
- Harris, A. G. (1994). Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. Gut. https://doi.org/10.1136/gut.35.3_suppl.s1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.